loading
Xeris Biopharma Holdings Inc stock is traded at $7.75, with a volume of 1.70M. It is up +2.11% in the last 24 hours and up +51.37% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$7.59
Open:
$7.6
24h Volume:
1.70M
Relative Volume:
0.71
Market Cap:
$1.25B
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-18.45
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
+0.91%
1M Performance:
+51.37%
6M Performance:
+106.67%
1Y Performance:
+176.79%
1-Day Range:
Value
$7.57
$7.79
1-Week Range:
Value
$7.27
$7.79
52-Week Range:
Value
$2.48
$7.79

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name
Name
Xeris Biopharma Holdings Inc
Name
Phone
844-445-5704
Name
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Name
Employee
394
Name
Twitter
@XerisPharma
Name
Next Earnings Date
2024-12-08
Name
Latest SEC Filings
Name
XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XERS
Xeris Biopharma Holdings Inc
7.75 1.19B 181.41M -59.56M -38.83M -0.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-12-25 Resumed H.C. Wainwright Buy
Nov-11-24 Downgrade Piper Sandler Overweight → Neutral
Mar-28-24 Initiated Oppenheimer Outperform
Aug-28-23 Initiated Craig Hallum Buy
Oct-21-22 Initiated Jefferies Buy
Apr-28-22 Initiated Craig Hallum Buy
Nov-17-21 Initiated SVB Leerink Outperform
Oct-29-21 Initiated H.C. Wainwright Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Feb-18-20 Initiated Piper Sandler Overweight
Jul-16-18 Initiated Jefferies Buy
Jul-16-18 Initiated Leerink Partners Outperform
Jul-16-18 Initiated RBC Capital Mkts Outperform
View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

pulisher
Aug 15, 2025

Johnson, director, sells Xeris Biopharma (XERS) shares for $786k - Investing.com

Aug 15, 2025
pulisher
Aug 15, 2025

Johnson, director, sells Xeris Biopharma (XERS) shares for $786k By Investing.com - Investing.com Nigeria

Aug 15, 2025
pulisher
Aug 15, 2025

Independent Director Dawn Halkuff Sold A Bunch Of Shares In Xeris Biopharma Holdings - simplywall.st

Aug 15, 2025
pulisher
Aug 15, 2025

Can Xeris Biopharma Holdings Inc. expand its profit margins2025 Market Outlook & Precise Swing Trade Alerts - sundaytimes.kr

Aug 15, 2025
pulisher
Aug 15, 2025

Tools to assess Xeris Biopharma Holdings Inc.’s risk profile2025 Earnings Impact & Weekly High Potential Stock Alerts - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Is Xeris Biopharma Holdings Inc. stock a good dividend stockQuarterly Portfolio Report & Stock Portfolio Risk Control - thegnnews.com

Aug 15, 2025
pulisher
Aug 14, 2025

Will Xeris Biopharma Holdings Inc. benefit from macro trendsMarket Performance Recap & Capital Efficiency Focused Ideas - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Insider Selling at Xeris Biopharma: A Signal or a Strategy? - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Xeris Biopharma Director Dawn Halkuff Sells 42,500 Shares at $7.28 Each. - AInvest

Aug 14, 2025
pulisher
Aug 13, 2025

Xeris Biopharma (NASDAQ:XERS) Upgraded at HC Wainwright - Defense World

Aug 13, 2025
pulisher
Aug 13, 2025

Dawn Halkuff sells Xeris Biopharma (XERS) shares worth $309k By Investing.com - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 13, 2025

Dawn Halkuff sells Xeris Biopharma (XERS) shares worth $309k - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

Xeris Biopharma (NASDAQ:XERS) Raised to “Buy” at HC Wainwright - Defense World

Aug 13, 2025
pulisher
Aug 13, 2025

How high can Xeris Biopharma Holdings Inc. stock goDollar Strength & Entry and Exit Point Strategies - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Xeris Biopharma (NASDAQ:XERS) Coverage Initiated by Analysts at HC Wainwright - Defense World

Aug 13, 2025
pulisher
Aug 13, 2025

Using Python tools to backtest Xeris Biopharma Holdings Inc. strategiesReal Time Stock Movement and Alerts - Newser

Aug 13, 2025
pulisher
Aug 12, 2025

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Xeris Biopharma Earns Buy Rating from HC Wainwright with $10 PT - AInvest

Aug 12, 2025
pulisher
Aug 11, 2025

Can trapped investors hope for a rebound in Xeris Biopharma Holdings Inc.Momentum Prediction Based on AI Backtesting - Newser

Aug 11, 2025
pulisher
Aug 10, 2025

How liquid is Xeris Biopharma Holdings Inc. stockSpeedy Gain Trade Picks - thegnnews.com

Aug 10, 2025
pulisher
Aug 10, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st

Aug 10, 2025
pulisher
Aug 10, 2025

Wyckoff Accumulation Phase Possible in Xeris Biopharma Holdings Inc.Potential Breakout Stock List Published This Week - beatles.ru

Aug 10, 2025
pulisher
Aug 10, 2025

Bollinger Bands Show Potential Breakout in Xeris Biopharma Holdings Inc.Day Trading Signals With High Precision Reviewed - beatles.ru

Aug 10, 2025
pulisher
Aug 09, 2025

How Xeris Biopharma Holdings Inc. stock performs during market volatilityForecast Model for Intraday Buy Signals - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Aug 09, 2025
pulisher
Aug 09, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 09, 2025
pulisher
Aug 09, 2025

Xeris Biopharma (NASDAQ:XERS) Sees Large Volume Increase Following Better-Than-Expected Earnings - Defense World

Aug 09, 2025
pulisher
Aug 09, 2025

Xeris Biopharma (NASDAQ:XERS) Upgraded to “Strong-Buy” at Wall Street Zen - Defense World

Aug 09, 2025
pulisher
Aug 08, 2025

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - NewsBreak: Local News & Alerts

Aug 08, 2025
pulisher
Aug 08, 2025

XERS (Xeris Biopharma Holdings) Momentum Rank : 3 (As of Aug. 08, 2025) - GuruFocus

Aug 08, 2025
pulisher
Aug 08, 2025

XERS Crosses Above Average Analyst Target - Nasdaq

Aug 08, 2025
pulisher
Aug 08, 2025

Xeris Biopharma Reports Record Q2 2025 Revenue, Raises Full-Year Guidance - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Xeris Biopharma: Q2 Earnings Snapshot - Connecticut Post

Aug 08, 2025
pulisher
Aug 08, 2025

Xeris Biopharma (NASDAQ:XERS) Sets New 52-Week High Following Earnings Beat - Defense World

Aug 08, 2025
pulisher
Aug 08, 2025

Xeris Biopharma Reports Strong Q2 2025 Results - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Beyond the Balance Sheet: What SWOT Reveals About Xeris Biopharm - GuruFocus

Aug 08, 2025
pulisher
Aug 07, 2025

Xeris raises 2025 revenue guidance to $280M–$290M following 49% Q2 growth, led by Recorlev - MSN

Aug 07, 2025
pulisher
Aug 07, 2025

Xeris Biopharma Holdings, Inc. SEC 10-Q Report - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Transcript : Xeris Biopharma Holdings, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Xeris Biopharma Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Little Excitement Around Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Revenues - 富途牛牛

Aug 07, 2025
pulisher
Aug 07, 2025

Xeris (XERS) Q2 Revenue Jumps 49% - The Motley Fool

Aug 07, 2025
pulisher
Aug 07, 2025

Xeris Biopharma shares rise 24.23% premarket after beating Q2 revenue expectations and raising FY guidance. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Xeris Biopharma Stock Soars 12.02% on Record Q2 Earnings - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance - BioSpace

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings Flash (XERS) Xeris Biopharma Posts Q2 Net Loss $0.01 a Share, vs. FactSet Est of $0.05 Loss - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Xeris Biopharma beats Q2 revenue expectations, raises FY guidance - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Mackenzie Financial Corp Has $780,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Aug 07, 2025
pulisher
Aug 06, 2025

Institutional scanner results for Xeris Biopharma Holdings Inc.Trade Flow Monitor with Volume Tracker - Newser

Aug 06, 2025

Xeris Biopharma Holdings Inc Stock (XERS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Xeris Biopharma Holdings Inc Stock (XERS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
HALKUFF DAWN
Director
Aug 12 '25
Sale
7.28
42,500
309,226
115,000
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):